An observational study in Refractory Multiple Myeloma (RRMM), sponsored by Pfizer. Active, not recruiting at 4 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Pfizer · Observational
The purpose of this study is to evaluate:
This study is seeking participants who:
Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's planned enrollment of 1 is below the median of 140 across 468 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Study population will consist of RRMM patients who have initiated elranatamab in consistent with the local health authority approved product label
Exclusion criteria:
Patients who participated in any prior clinical trials using elranatamab.
Patients with Relapsed and/or Refractory Multiple Myeloma treated with Elranatamab
Drug: Non intervention
Non intervention
rwTTR (real-world time to response)
Time from index date to the first documented real-world response.
Time frame: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
rwORR (real-world overall response rate)
Proportion of patients achieving real-world overall response at predefined assessment time points.
Time frame: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
rwDOR (real-world duration of response）
Time from the first documented real-world response to real-world disease progression, death, or end of study.
Time frame: From first response until 18 months
rwPFS (real-world progression-free survival)
Time from index date to the first documented real-world disease progression or death.
Time frame: From initiation of elranatamab treatment (index date) until 18 months
rwOS (real world overall survival)
Time from index date to death from any cause.
Time frame: From initiation of elranatamab treatment (index date) until 18 months
rwTTNT (real world time to next treatment)
Time from index date to initiation of the next line of anti-myeloma therapy or end of study.
Time frame: From initiation of elranatamab treatment (index date) until 18 months
Demographic: Age
Age (measured in years)
Time frame: At baseline
Demographic: Sex
sex/gender (male/female)
Time frame: From MM diagnosis until index date, and from index date until 18 months
Anthropometric Measures
Height (in cm), weight (in kg), BMI (kg/m²),
Time frame: At baseline
ECOG Performance Status
Number and proportion of patients in each ECOG PS category (0-5)
Time frame: At baseline
Myeloma-related Clinical Characteristics
Baseline disease characteristics including myeloma type (IgG, non-IgG, light-chain, non-secretory), bone marrow plasma cell %, presence of EMD, ECOG status, CRAB symptoms, ISS/R-ISS stage, MGUS, SMM, and cytogenetic risk.
Time frame: At baseline
Laboratory Characteristics
Baseline laboratory result of creatinine clearance (CrCl) categories (stages 1-5 or \<30/≥30 mL/min)
Time frame: At baseline
Prior Treatment History
Number and proportion of patients with prior ASCT, prior anti-MM therapies
Time frame: At baseline
Time from Diagnosis and Line of Elranatamab Treatment
Time from MM diagnosis to elranatamab initiation.
Time frame: From the index date (initiation of elranatamab treatment) up to 18 months
Elranatamab Discontinuation and Treatment Modifications
Number and proportion of patients with treatment discontinuation (and reasons), dosing or schedule modifications (excluding step-up), and switches from QW to Q2W after 6 cycles.
Time frame: From the index date (initiation of elranatamab treatment) up to 18 months
Subsequent Treatments After Progression
Number and proportion of patients receiving subsequent treatments following first progression or discontinuation of elranatamab.
Time frame: From the index date (initiation of elranatamab treatment) up to 18 months
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer